Quick Answer
Citius Pharmaceuticals, Inc. reported Total Revenue of $0.00 for fiscal year 2013.
Citius Pharmaceuticals, Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | — | — | -$32.54M +3.3% |
-$33.64M -45.9% |
-$23.05M -31.4% |
-$17.55M -12.8% |
| Diluted EPS | -$3.38 +43.4% |
-$5.97 -7.2% |
-$5.57 -2321.7% |
-$0.23 +0.0% |
-$0.23 | — |
| Total Assets | $130.94M +12.2% |
$116.65M +12.6% |
$103.61M -9.1% |
$114.00M -20.0% |
$142.43M +225.4% |
$43.77M +19.1% |
| Cash and Equivalents | $4.25M +30.8% |
$3.25M -87.7% |
$26.48M -36.5% |
$41.71M -40.5% |
$70.07M +405.6% |
$13.86M +75.6% |
| Stockholders Equity | $67.55M -3.6% |
$70.08M -22.8% |
$90.83M -11.7% |
$102.83M -22.2% |
$132.18M +292.6% |
$33.67M +24.0% |
| R&D Expense | $9.16M -23.1% |
$11.91M -19.7% |
$14.82M -16.1% |
$17.66M +44.2% |
$12.24M +38.9% |
$8.81M +2.5% |
| Operating Income | -$38.53M +8.3% |
-$42.00M -14.3% |
-$36.73M -10.3% |
-$33.32M -41.6% |
-$23.53M -32.9% |
-$17.71M -13.5% |
| Shares Outstanding | 18.07M +149.3% |
7.25M +14.1% |
6.35M -95.7% |
146.21M +0.2% |
145.98M +162.7% |
55.58M +92.1% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | December 31, 2025 | $3.94M | — | — |
| Net Income | March 31, 2025 | -$11.51M | -34.7% | -12.0% |
| Diluted EPS | December 31, 2025 | -$0.38 | +70.8% | +52.5% |
| Total Assets | December 31, 2025 | $140.39M | +16.3% | +7.2% |
| Cash and Equivalents | December 31, 2025 | $7.72M | +601.9% | +81.6% |
| Stockholders Equity | December 31, 2025 | $79.96M | +22.2% | +18.4% |
| R&D Expense | December 31, 2025 | $1.60M | -24.8% | -1.3% |
| Operating Income | December 31, 2025 | -$9.02M | +10.2% | -2.6% |
| Gross Profit | December 31, 2025 | $3.15M | — | — |
| Shares Outstanding | December 31, 2025 | 22.38M | +189.6% | +23.8% |
- Citius Pharmaceuticals, Inc. reported Total Revenue of $0.00 for fiscal year 2013.
- Citius Pharmaceuticals, Inc. reported Net Income of -$32.54 million for fiscal year 2023.
- Citius Pharmaceuticals, Inc. showed an increase of +3.3% in Net Income compared to the prior fiscal year.
- Citius Pharmaceuticals, Inc. reported Diluted EPS of $3.38 per share (loss) for fiscal year 2025.
- Citius Pharmaceuticals, Inc. showed an increase of +43.4% in Diluted EPS compared to the prior fiscal year.
- Citius Pharmaceuticals, Inc. reported Total Assets of $130.94 million for fiscal year 2025.
- Citius Pharmaceuticals, Inc. showed an increase of +12.2% in Total Assets compared to the prior fiscal year.
- Citius Pharmaceuticals, Inc. reported Cash and Equivalents of $4.25 million for fiscal year 2025.
- Citius Pharmaceuticals, Inc. showed an increase of +30.8% in Cash and Equivalents compared to the prior fiscal year.
- Citius Pharmaceuticals, Inc. reported Stockholders Equity of $67.55 million for fiscal year 2025.
- Citius Pharmaceuticals, Inc. showed a decrease of -3.6% in Stockholders Equity compared to the prior fiscal year.
- Citius Pharmaceuticals, Inc. reported R&D Expense of $9.16 million for fiscal year 2025.
- Citius Pharmaceuticals, Inc. showed a decrease of -23.1% in R&D Expense compared to the prior fiscal year.
- Citius Pharmaceuticals, Inc. reported Operating Income of -$38.53 million for fiscal year 2025.
- Citius Pharmaceuticals, Inc. showed an increase of +8.3% in Operating Income compared to the prior fiscal year.
- Citius Pharmaceuticals, Inc. reported Shares Outstanding of 18.07 million shares for fiscal year 2025.
- Citius Pharmaceuticals, Inc. showed an increase of +149.3% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: